Web Desk 
bluebird bio, Inc. (NASDAQ: BLUE) today released its financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.
“For more than ten years, bluebird bio has pioneered gene therapies for rare disease and cancer patients, and our work continues with the analysis of recent safety events identified in our HGB-206 study in patients. with sickle cell anemia. We have seen the transformative benefits of these therapies and are conducting a scientific and medical investigation to better inform our way forward on behalf of the patients we hope to serve with LentiGlobin, ”said Nick Leschly, Bluebird Leader. “While…
Read Additional From Source
Copyright @ finance.yahoo.com
News Highlights Finance
- Headline: bluebird bio releases fourth quarter and full year 2020 financial results and provides operational progress update
- Check all news and articles from the Finance news updates.
For Latest Updates Follow us on Google News
- Show all
- Trending
- Most Viewed
